Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,981

Document Document Title
WO/2018/213426A1
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. The compounds have the formula (I) wherein R is H or CH2OPO(OH)2. Also provided are pharmaceutical compositions comprising th...  
WO/2018/206728A1
The invention relates to the use of a precursor for the production of carbon-11-labelled amino acids or derivatives thereof. According to the invention, the precursor is a compound of formula I: (formula I), where R1 and R2 are selected ...  
WO/2018/189560A1
The invention relates to a process for post-preparation labelling of liposomal formulations with F (fluorine) isotope, wherein a) during the preparation of the liposomal formulation, a phospholipid derivative modified by terminal alkyne ...  
WO/2018/176253A1
Provided are a group of isotope labelling reagents for carboxyl labelling and a synthesis method therefor, wherein one end of the isotope labelling reagent is a primary amine and the other end is a trimethyl ammonium salt; and the primar...  
WO/2018/176512A1
The invention falls within the technical field of pharmaceutical compounds, and in particular relates to a deuterated palbociclib derivative, a preparation method and the use thereof. The deuterated palbociclib derivative has a structure...  
WO/2018/183406A1
Composition, manufactures, and methods of making and using them, illustratively a process including the steps of: changing density of a composition including a neutron absorbent, the absorbent having a neutron absorption cross section gr...  
WO/2018/171816A1
Disclosed in the present invention are a deuterated dipeptide boronic acid or an ester compound thereof, or a crystalline form, pharmaceutically acceptable hydrate or solvate thereof, the structure thereof being shown in formula (a), whe...  
WO/2018/172243A1
The present invention is directed towards isomerically pure 18F-labelled (6S)-or (6R)-5-methyltetrahydrofolate radiopharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an 18F-labelled N-heterocycle...  
WO/2018/168643A1
Provided is a method for producing [123I] ioflupane in a large quantity without deteriorating the quality thereof. The method is a method for producing radioactive-iodine-labeled ioflupane, comprising the steps of (a) reacting a labeling...  
WO/2018/164043A1
Provided is a labeled precursor compound represented by formula (2). (In the formula, S represents a substrate, L represents a C1-6 linear alkyl group which may contain an ether group, R1 and R2 each independently represent a C1-30 linea...  
WO/2018/165185A1
Long-term and high-density energy sources are described that utilize radioisotope batteries that provide a tritium (3H)-based direct energy conversion system. The beta radiation source is a nitroxide compound with a synthetic yield near ...  
WO/2018/158137A1
The present invention provides a process to enhance the productivity such as yield of radioactive fluorine labeled flutemetamol. Provided is a process for producing a radioactive fluorine labeledflutemetamol, which comprises: (a) a step ...  
WO/2018/153966A1
The present invention relates to novel compounds useful for visualizing cell sen es c en ce in vitro and in vivo, the preparation of said compounds and their use. In particular, the present invention pertains to novel hexose and particul...  
WO/2018/153507A1
Compounds of formula (I), wherein R', R'', R, X, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2018/148113A1
The present invention is directed to 13C and/or 2H isotope enhanced ambroxol ("isotope enhanced ambroxol") and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditi...  
WO/2018/146116A1
The present invention relates to in vivo stable 197(m)Hg compounds according to formula (I) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the produc...  
WO/2018/144101A1
Described herein are labeling agents, specifically [11C]fluoroform, [11C]difluoromethane, [11C]fluoromethyl iodide, [11C]fluoromethyl bromide, [11C]fluoromethyl chloride, [11C]fluoromethyl trifluoromethansulfonate, [11C]difluoromethyl io...  
WO/2018/115353A1
The present invention relates to a method for conditioning reversed phase SPE cartridges that provides certain advantages compared with known such methods. The method of the invention finds particular use in the automated synthesis of ra...  
WO/2018/115148A1
The present application provides a means for differential diagnosis of Parkinson's disease and the clinically similar Parkinsonian disorders multiple system atrophy with predominantly Parkinsonian features (MSA-P) and progressive supranu...  
WO/2018/106916A1
This invention relates to novel 2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1, 2,3-de]quinoxalines, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this inve...  
WO/2018/099271A1
The prevent invention provides a method for preparing deuterated chemicals, and deuterated chemicals. The method comprises the step of: making halides undergo a deuteration reaction with a deuterium source under the catalytic action of a...  
WO/2018/095386A1
Disclosed in the present invention are a fused ring compound and applications thereof in organic electronic components, particularly in organic electroluminescent diodes. Also disclosed in the present invention are an organic electronic ...  
WO/2018/094116A1
Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopicaliy-modified polyunsaturated fatty acid, an isotopicaliy-modified polyunsat...  
WO/2018/081858A1
The present invention relates to new desferrioxamine B analogues that are useful for iron-chelation therapy, to their preparation including intermediates, and to compositions including the compounds. The present invention also relates to...  
WO/2018/080591A1
Disclosed is a method of treating in a subject of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator. The method comprises administering to the subject Compoind (I) or pharmaceutically acce...  
WO/2018/072300A1
Disclosed is a method for preparing a deuterated imidazole diketone compound, comprising the following steps: (1) using a compound of formula (I) and a compound of formula (II) as raw materials to obtain a compound of formula (III) by me...  
WO/2018/067771A1
Tin(IV)-117m is reduced by an acidic antimony solution to tin(II)-117m. A chelant is added to the solution of tin(II)-117m, and the pH is raised, forming tin(II)-117m chelant complex. The chelant is a bifunctional chelant, preferably att...  
WO/2018/064092A1
Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors...  
WO/2018/046662A1
The present invention relates to a positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [18F] -labelled lactate derivative. The invention also provides a process for the radiosynthesis of the...  
WO/2018/037097A1
The present invention concerns a method for preparing a microorganism hydrolysate of which at least one amino acid and/or one amino acid precursor is labelled, comprising a step of obtaining a microorganism hydrolysate in solution in whi...  
WO/2018/035610A1
The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging: (Formula (I)).  
WO/2018/028541A1
Provided is a substituted quinoline compound and a pharmaceutical composition and a use thereof.The quinoline compound is a compound as shown in formula (I), or a crystal form, a pharmaceutically acceptable salt, a hydrate or a solvate t...  
WO/2018/024642A1
The invention relates to 9H-pyrrolo-dipyridine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection ...  
WO/2018/023116A1
Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify β-N-methylamino-L-alanine (BMAA) in a sample. The reagents can be used as stable ...  
WO/2018/022125A1
Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid tumors, have the formula: [Formula sh...  
WO/2018/022603A1
Described herein are novel methods for the synthesis of radiolabeling synthons such as [18F]fluoronicotinic acid-2,3,5,6-tetrafluorophenyl ester, and also methods of labeling a protein or peptide comprising a free amine group. A novel c-...  
WO/2018/023115A1
Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify β-N-methylamino-L-alanine (BMAA) in the Cu/Zn Superoxide Dismutase 1 (SOD1) prote...  
WO/2018/015307A1
The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising ...  
WO/2018/015549A1
The present invention relates to novel compounds of the formula (II) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies usin...  
WO/2018/015546A1
The present invention relates to novel compounds of the formula (I) that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using...  
WO/2018/008311A1
[Problem] To provide 11C-labelled O6-benzylguanine with which PET images can be obtained, and a production method therefor. [Solution] This 11C-labelled O6-benzylguanine is characterized by being represented by chemical formula (a). The ...  
WO/2018/005625A1
The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula (I) or a pharmace...  
WO/2017/210302A1
Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.  
WO/2017/206801A1
Disclosed are a class of diarylsulfide derivatives, a preparation method therefor, and the use thereof as a serotonin transporter-targeted imaging agent, belonging to the field of radiopharmaceutical chemistry. The diarylsulfide derivati...  
WO/2017/202206A1
The present invention discloses a substituted quinoline compound as shown in formula (I), a pharmaceutical composition comprising said compound or a polymorph, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, an isotopic va...  
WO/2017/191604A3
The invention relates to a process for the preparation of complexes of the 68Ga radioisotope in which the complexation reaction between a chelator- functionalised molecule and 68Ga occurs in the presence of a neutralising agent (preferab...  
WO/2017/181918A1
The present invention discloses a substituted phthalazone, wherein the substituted phthalazone is a compound represented by formula (I). The invention further discloses a pharmaceutical composition comprising the compound, or a crystalli...  
WO/2017/180492A1
A system, and method, for quantitatively mapping of mitochondrial membrane potential of a tissue in a subject is provided. In some aspects, the provided method includes administering to the subject a detectably effective amount of a trac...  
WO/2017/180589A1
The present disclosure provides compounds of Formula I and/or Formula II, or pharmaceutically acceptable salts thereof: wherein D is deuterium and each deuterium has deuterium enrichment of no less than about 10%, compositions containing...  
WO/2017/157137A1
Provided in the present invention is a new type acyclic nucleoside analogue and a pharmaceutical composition thereof, wherein the new type nucleoside analogue is the compound as shown by formula (I), or a crystal form, a pharmaceutically...  

Matches 1 - 50 out of 1,981